138 related articles for article (PubMed ID: 19893679)
1. Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective.
Sharma SR; Sharma N
Ann Indian Acad Neurol; 2008 Oct; 11(4):231-5. PubMed ID: 19893679
[TBL] [Abstract][Full Text] [Related]
2. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
[TBL] [Abstract][Full Text] [Related]
4. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Hotta N; Kawamori R; Atsumi Y; Baba M; Kishikawa H; Nakamura J; Oikawa S; Yamada N; Yasuda H; Shigeta Y;
Diabet Med; 2008 Jul; 25(7):818-25. PubMed ID: 18644069
[TBL] [Abstract][Full Text] [Related]
5. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
Steele JW; Faulds D; Goa KL
Drugs Aging; 1993; 3(6):532-55. PubMed ID: 8312678
[TBL] [Abstract][Full Text] [Related]
6. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
7. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of epalrestat plus α-lipoic acid combination therapy
Zhao M; Chen JY; Chu YD; Zhu YB; Luo L; Bu SZ
Neural Regen Res; 2018 Jun; 13(6):1087-1095. PubMed ID: 29926837
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
[TBL] [Abstract][Full Text] [Related]
10. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway.
Li QR; Wang Z; Zhou W; Fan SR; Ma R; Xue L; Yang L; Li YS; Tan HL; Shao QH; Yang HY
Neural Regen Res; 2016 Feb; 11(2):345-51. PubMed ID: 27073391
[TBL] [Abstract][Full Text] [Related]
11. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R
Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats.
Ota A; Kakehashi A; Toyoda F; Kinoshita N; Shinmura M; Takano H; Obata H; Matsumoto T; Tsuji J; Dobashi Y; Fujimoto WY; Kawakami M; Kanazawa Y
J Diabetes Res; 2013; 2013():175901. PubMed ID: 23671855
[TBL] [Abstract][Full Text] [Related]
13. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
15. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
Airey M; Bennett C; Nicolucci A; Williams R
Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
[TBL] [Abstract][Full Text] [Related]
16. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
[TBL] [Abstract][Full Text] [Related]
17. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
18. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
19. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
